| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Medicine (B.A.) and Physiological Sciences (N.W., F.S.), Lund University, SE-221 84 Lund, Sweden; Metabolic Unit, Institute of Biomedical Engineering, National Research Council (G.P.), 35127 Padova, Italy; and Department of Medicine (D.W.), Bristol University, Bristol BS2 8HW, United Kingdom
Address all correspondence and requests for reprints to: Dr. Bo Ahrén, Department of Medicine, Lund University, B11 Biomedical Centre, SE-221 84 Lund, Sweden. E-mail: Bo.Ahren{at}med.lu.se.
The neuropeptide galanin is expressed in sympathetic nerve terminals that surround islet cells and inhibits insulin secretion. To explore its role for islet function, we studied mice with a loss-of-function mutation in the galanin gene [galanin knockout (KO) mice]. Intravenous 2-deoxy-glucose, which activates both the sympathetic and parasympathetic branches of the autonomic nervous system, caused an initial (15 min) inhibition of insulin secretion that was impaired in galanin KO mice (P = 0.027), followed by a subsequent stimulation of insulin secretion that was augmented in galanin KO mice (P < 0.01). Similar effects were seen after chemical sympathectomy by 6-hydroxydopamine. In contrast, galanin KO mice had a reduced insulin response to glucose, both in vivo (P < 0.001) and in isolated islets (P < 0.001), and to arginine, both in vivo (P = 0.012) and in vitro (P = 0.018). During an iv glucose tolerance test, galanin KO mice had impaired glucose disposal (P = 0.005) due to a reduced insulin response (P < 0.001) and a reduced insulin-independent glucose elimination (glucose effectiveness; P = 0.040). Insulin sensitivity, as judged by a euglycemic, hyperinsulinemic clamp technique, was slightly increased in galanin KO mice (P = 0.032). We conclude that 1) galanin may contribute to sympathetic influences inhibiting insulin secretion in mice, and 2) galanin KO mice have a reduced glucose-induced insulin secretion.
This article has been cited by other articles:
![]() |
B. Ahren, N. Wierup, and F. Sundler Neuropeptides and the Regulation of Islet Function Diabetes, December 1, 2006; 55(Supplement_2): S98 - S107. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Wierup, M. Bjorkqvist, M. J. Kuhar, H. Mulder, and F. Sundler CART Regulates Islet Hormone Secretion and Is Expressed in the {beta}-Cells of Type 2 Diabetic Rats Diabetes, February 1, 2006; 55(2): 305 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Ayala, D. P. Bracy, O. P. McGuinness, and D. H. Wasserman Considerations in the Design of Hyperinsulinemic-Euglycemic Clamps in the Conscious Mouse Diabetes, February 1, 2006; 55(2): 390 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Henquin Pathways in Beta-Cell Stimulus-Secretion Coupling as Targets for Therapeutic Insulin Secretagogues Diabetes, December 1, 2004; 53(suppl_3): S48 - S58. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |